PRMA Insights: The Roadmap to Pricing and Reimbursement Success

The NSCLC report delivers

Use this report to gain an understanding of the following issues in the pricing and reimbursement of NSCLC in the major markets:

• The key pricing and reimbursement issues and treatments by country and the implications for products seeking nominations for NSCLC is now critical to commercial success.
• How payers have critically evaluated the data packages for existing NSCLC products.
• An in-depth critical review of over 25 NSCLC pricing and reimbursement and HTA assessments in NSCLC in the major markets.
• The price existing products have achieved and their reimbursement status in each country.
• The value propositions and arguments manufacturers have submitted for their products.
• A review of the relevant risk sharing agreements for products indicated for NSCLC.
• An overview of NSCLC with a focus on the key issues shaping the market access landscape.
• The implications surrounding the choice of comparators and endpoints included in the clinical trials in pricing and reimbursement.
• A comprehensive review of NSCLC products, regulatory nominations, key supporting data packages and the position in clinical guidelines.
  
• The key learnings and market access insights for developing a new product in NSCLC.
  
• How payers view combination and maintenance therapy.
  
• A review of the epidemiology and burden of NSCLC with insights into evidence gaps and the impact on your health outcomes strategy.
  
• A review of the existing instruments used to measure Health Related Quality of Life (HRQoL) in NSCLC, opportunities for the inclusion of HRQoL data in your label and how this could differentiate your product and impact pricing and reimbursement. 
  
  

Find out more about the NSCLC report:

The report delivers         Scope of the report        Authors of the report